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Abstract
Background: Trypanosoma cruzi is a Kinetoplastid parasite of humans and is the cause of Chagas
disease, a potentially lethal condition affecting the cardiovascular, gastrointestinal, and nervous
systems of the human host. Constraint-based modeling has emerged in the last decade as a useful
approach to integrating genomic and other high-throughput data sets with more traditional,
experimental data acquired through decades of research and published in the literature.
Results: We present a validated, constraint-based model of the core metabolism of Trypanosoma
cruzi strain CL Brener. The model includes four compartments (extracellular space, cytosol,
mitochondrion, glycosome), 51 transport reactions, and 93 metabolic reactions covering
carbohydrate, amino acid, and energy metabolism. In addition, we make use of several replicate
high-throughput proteomic data sets to specifically examine metabolism of the morphological form
of T. cruzi in the insect gut (epimastigote stage).
Conclusion: This work demonstrates the utility of constraint-based models for integrating various
sources of data (e.g., genomics, primary biochemical literature, proteomics) to generate testable
hypotheses. This model represents an approach for the systematic study of T. cruzi metabolism
under a wide range of conditions and perturbations, and should eventually aid in the identification
of urgently needed novel chemotherapeutic targets.

Background
The increasing availability of complete genome sequences
has spurred efforts to model biological systems on a comprehensive scale [1,2]. Constraint-based modeling has
emerged in the last decade as a useful approach to the

integration of genomic and other high-throughput data
sets with more traditional, experimental data acquired
through decades of biochemical and molecular research
[3,4]. To date, constraint-based modeling has been extensively applied to probe the function of intracellular
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metabolism, although the constraint-based framework is
in principle applicable to any set of chemical transformations, including signal transduction networks [5] and
transcription or translation [6]. When combined with a
specific method of analysis, e.g., flux balance analysis
(FBA), constraint-based models can be used to generate
quantitative predictions (e.g., growth rate of an organism)
and yield testable hypotheses for future experimental
investigations [7]. This permits an iterative process of
model development, hypothesis generation and testing,
and further model development and refinement [8]. The
principles and methods of building and analyzing constraint-based models have been comprehensively
reviewed in the literature [6,9,10]. Experimentally validated constraint-based models are providing integrative,
systems-level views of the functioning of different metabolic networks of various organisms across a wide range
of specific conditions (e.g., gene deletions, pharmacological interventions and environmental perturbations) [1114].

http://www.biomedcentral.com/1752-0509/3/52

51 transport reactions, and 93 metabolic reactions covering carbohydrate, amino acid, and energy metabolism. In
addition, we make use of several replicate high-throughput proteomic data sets to specifically examine metabolism of the morphological form of the parasite in the
insect gut, or epimastigote stage of T. cruzi (see Methods
for details on T. cruzi life-cycle). In doing so, we demonstrate the utility of constraint-based models for integrating
various sources of information (e.g., genomics, primary
biochemical literature, proteomics) to generate testable
hypotheses. Previous work has used sequence analysis of
the T. cruzi genome to produce improved annotations and
thus extend our understanding of T. cruzi metabolism
[28,29]. However the model reported here is the first constraint-based model of T. cruzi of which we are aware. It
represents an approach to the systematic study of T. cruzi
metabolism under a wide range of conditions and perturbations for the identification of novel chemotherapeutic
targets.

Results
Trypanosoma cruzi is a protozoan parasite of the order
Kinetoplastida that infects humans and a wide variety of
other mammals. Like other members of its order, T. cruzi
is characterized by a single mitochondrion containing a
complex network of DNA fibrils known as the kinetoplast
[15]. T. cruzi displays many unusual biological features:
specialized intracellular compartments, such as the glycosome (in which the initial reactions of glycolysis occur)
[16,17], acidocalcisome [18], and reservesome [19]; widespread RNA editing of mitochondrial transcripts [20];
polycistronic transcription [21]; and trans-splicing [22],
to name a few. Its life cycle is complex, involving multiple
distinct morphologic stages in both its mammalian hosts
and the triatomine insect vectors [15]. T. cruzi is the causative agent of Chagas disease, a potentially lethal condition affecting the cardiovascular, gastrointestinal, and
nervous systems of the human host. The impact of Chagas
disease is significant; approximately 10 million persons
are affected, primarily in Latin America [23], and life
expectancy is reduced by 9 years in those patients who
develop chronic symptoms [24]. Despite decades of
research, only two drugs, nifurtimox and benznidazole,
have proven useful in treating this disease [25]. However,
the efficacy of these drugs for chronic Chagas disease is far
below 100 percent [26,27] and both are associated with
significant adverse effects, such as peripheral neuropathy
and central nervous system toxicity [25].
To permit a systems-level understanding of this parasite
and to provide a basis for detailed modeling of host-parasite interactions, we present a validated, constraint-based
model of T. cruzi strain CL Brener core metabolism. The
model, hereafter referred to as iSR215 (see Methods for
model naming convention), includes four compartments,

Properties of iSR215
The iSR215 network reconstruction accounts for the function of 215 genes and includes 162 reactions, of which
144 are metabolic reactions and 18 are exchange reactions
(Table 1, see also additional file 1: DetailedResults.xls, for
model in spreadsheet form and additional file 2: tcr.xml,
for model in SBML format). Of the exchange reactions, 17
are input-output exchanges that allow metabolites to
enter and/or leave the model system, and one is the biomass demand reaction used to drain metabolites assumed
critical to the growth of T. cruzi (e.g., glucose-6-phosphate, pyruvate and oxaloacetate). Of the reactions in
iSR215, 76 are supported by both genomic and direct biochemical evidence (e.g., enzyme activity measured) in T.
cruzi, and 100 reactions are supported by genomic or literature-derived evidence in T. cruzi or related organisms.
Most reactions not associated with literature-based evidence are intracellular transports, reflecting the fact that
little is known about such processes in T. cruzi.
Table 1: Properties of iSR215

Property

Count

Genes
Reactions
Gene associated
Non-gene associated (intracellular)
Non-gene associated (transport)
Exchange
Input-output
Demand (biomass)
Metabolites
Compartments
Literature References

215
162
92
1
51
18
17
1
158
4
182
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Figure 1 provides an overview of the reactions of iSR215
as grouped by pathway and compartment. As illustrated
in panel A, several central pathways of metabolism are
fully or partially included: glycolysis, tricarboxylic acid
(TCA) cycle, the pentose phosphate pathway, oxidative
phosphorylation, and metabolism of various amino
acids. Most reactions are part of carbohydrate metabolism
(including glycolysis, the pentose phosphate pathway,
and pyruvate metabolism). Further, as depicted in panel
B, reactions are distributed across three intracellular compartments – cytosol, glycosome, and mitochondrion –
and the extracellular compartment. The membrane-span-
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ning group consists of reactions that involve the transfer
of metabolites between subcellular compartments as well
as between the cytosol and extracellular space. Because
iSR215 contains four compartments, there are many
membrane-spanning reactions included (a total of 58).
The glycosome of T. cruzi is thought to be relatively
impermeable to metabolites, especially to adenine nucleotides and NAD(H) [30]; thus, this compartment must be
both energy and reduction-oxidation balanced. Accordingly, iSR215 contains no reactions transporting ATP/
ADP/ATP or NAD(H) between the glycosome and cytosol,
i.e., in any feasible solution, there is no net change in ATP/
ADP ratio or in NAD+/NADH ratio within the glycosome.
Furthermore, the model also accounts for substrate level
and proton motive force coupled ATP synthesis, as well as
the synthesis of various intermediate metabolites critical
to the formation of biomass (e.g., acetyl-CoA).
Defining epimastigote stage-specific metabolism
We used cultured T. cruzi epimastigotes to generate several
large replicate proteomic data sets (see Methods). A total
of 1047 distinct proteins were identified across 8 epimastigote samples. Many of the identified proteins were not
associated with any well-defined function (660 proteins
annotated as hypothetical). Of the identified proteins that
were linked to functions, the most commonly occurring
functional categories were metabolic processes (133) and
translation (110). Some of the more commonly occurring
functional subcategories of metabolic processes were:
nucleobase, nucleoside, nucleotide and nucleic acid metabolic processes (68); amino acid and derivative metabolic processes (61); and carbohydrate metabolism (44).
The complete proteomics results can be found in additional file 1: DetailedResults.xls.

Figure
Breakdown
1 of T. cruzi core metabolic network
Breakdown of T. cruzi core metabolic network. Depiction of the content of iSR215 with reactions categorized by
pathway (panel 1A) or by compartment (panel 1B). The
model includes several of the core pathways of metabolism.
Transport, or membrane spanning reactions are a sizeable
fraction of all reactions since this is a multicompartment
model of T. cruzi metabolism, including glycosomal and mitochondrial compartments.

The proteomics data were used to constrain iSR215 (the
"full model," with all reactions available) to an epimastigote stage-specific model (the "epimastigote model," with
some reaction fluxes set to zero). If there was no evidence
for the expression of a given protein in the epimastigote
stage, the upper and lower bounds of the corresponding
reaction (catalyzed by the protein) were constrained to
zero, thereby restricting the flux of the reaction to zero. In
the case of a reaction catalyzed by an enzyme complex, we
allowed the reaction to occur (i.e., did not constrain the
flux to zero) if any protein component of the complex was
detected by the proteomics experiment.
A graphical depiction of a section of the compartmentalized reconstruction is shown in figure 2 (the entire reconstruction is depicted
in additional file
3:
CruziCoreMetabolicNetwork.pdf). All of the reactions
illustrated in the map are present in the "full" model.
However, the fluxes of the reactions colored in black are
constrained to zero in the "epimastigote" case, effectively
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Figure
T.
cruzi core
2 metabolic network model, section
T. cruzi core metabolic network model, section. A map illustrating a section of the core metabolic network model of T.
cruzi. The model accounts for 144 intracellular and transport reactions, 17 input/output exchange reactions and 1 biomass
demand reaction across four compartments: cytosol, mitochondria, glycosome and extracellular space. Reactions colored in
green are present in both the full and epimastigote specific reconstructions. Those reactions present only in the full network
and not present in the epimastigote (i.e. flux is constrained to zero) are depicted in black. Exchange reactions are shown in red
(metabolites allowed to only enter the system), blue (metabolites allowed to only leave the system) and yellow (metabolites
allowed to enter and/or leave the system). The map also indicates the lower and upper flux constraints for each reaction
shown. For a depiction of the entire model, please see additional file 3: CruziCoreMetabolicNetwork.pdf.
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removing them from the network. Exchange reactions that
allow metabolites to only enter the system from the surrounding environment are colored in red. Further,
exchange reactions that allow metabolites to only leave
the system are in blue, and those reactions that allow
metabolites to either enter or leave the system are colored
in yellow. Intracellular reactions that are colored green are
associated with default constraints at the start of the simulation experiments.
Graphical representations of flux distributions calculated
using the genome-based full model and the epimastigote,
stage-specific model are depicted as additional files (additional file 4: FullModelFluxes.pdf and additional file 5:
EpimastigoteFluxes.pdf). Comparison of these results
reveals redistribution of fluxes involving multiple areas of
the metabolic map. One example is substrate level phosphorylation in the mitochondrion. In the full model, ATP
is generated by succinate-CoA ligase (SUCOASm) as part
of a cycle involving acetate-succinate CoA-transferase
(ASCTmr); in the epimastigote model, this same reaction
generates ATP as part of the TCA cycle. This is due to the
fact that ASCTmr flux is constrained to zero in the epimastigote model. Mitochondrial fumarate reductase (FRDm)
activity increases from zero flux in the full model to relatively high flux in the epimastigote model. This is likely
due to the inactivity of complex I in the epimastigote, with
reoxidation of NADH largely taken over by FRDm. Correctly accounting for stage-specific features of metabolism
is an important step to more accurately modeling metabolism.
Reaction lethality predictions
In silico predictions of lethality can be made at the level of
genes or reactions using constraint based models. Many of
the reactions in iSR215 are associated with isozymes (see
additional file 1: DetailedResults.xls). In these cases, in silico deletion of one gene will not result in a lethal prediction, even if the reaction itself is critical for the growth of
the parasite. Thus, we focus here on the set of reactions predicted to be lethal, as this provides a better view of critical
points in the network, i.e., those reactions which if
blocked by a chemotherapeutic would lead to the inability of the parasite to replicate (a complete listing of reactions predicted to be essential can be found in the
additional file 1: DetailedResults.xls).

All reactions in iSR215 were classified as lethal or nonlethal by systematically constraining the upper and lower
flux bounds of each reaction to be zero flux, and attempting FBA under defined in silico medium conditions (see
Methods). As shown in table 2, total of 26 reactions were
predicted to be essential in the full model, and 40 were
predicted to be essential in the epimastigote-specific
model. Of the 14 reactions with different essentialities in
the full and epimastigote models, three were the result of
the zero flux constraint on aldose-1-epimerase in the epimastigote model. Without this capability, reactions that
circumvent the inability to interconvert alpha- and betaglucose anomers became critical. Four reactions had different essentialities that resulted from the zero flux constraint
on
glycosomal
glycerol-3-phosphate
dehydrogenase and glycerol kinase in the epimastigote
model. Without these activities, reactions allowing the
regeneration of NAD via glycosomal fumarate reductase
became critical. Six reactions had different essentialities
between the two networks because of the zero flux constraint on threonine dehydrogenase in the epimastigote
model. In the absence of this activity, reactions permitting
acetyl-CoA production via pyruvate became critical.
We also simulated all possible double reaction deletions,
i.e., simultaneous elimination of two reactions. In total,
there were 10440 double deletions. In the full model,
1968 of these cases proved to be lethal. Most of these
(1872) were "trivial" in that the double deletion involved
at least one reaction that was lethal in a single deletion.
There were 96 non-trivial double deletions, i.e., involving
reactions that, while not lethal individually, were lethal
when deleted together. In the epimastigote model, there
were 3063 lethal double deletions, including 2880 trivial
and 183 non-trivial cases. For a complete listing of all single and non-trivial double reaction deletions, see additional file 1: DetailedResults.xls. Each of these predictions
represents a potentially testable hypothesis. Reactions
that are experimentally shown to be lethal are of special
interest, as these may correspond to novel chemotherapeutic targets.
Validating network analysis with experimental data
As a simple check on the validity of iSR215 network
reconstruction, we used the model to determine byproducts of metabolism under aerobic and anaerobic in silico

Table 2: Predicted reaction lethality

Full Model
Epimastigote

Deletion Level

Lethal

Trival Lethal

NonTrivial Lethal

NonTrivial Total

Total Cases

Single
Double
Single
Double

26
1968
40
3063

0
1872
0
2880

26
96
40
183

145
8568
145
7560

145
10440
145
10440

Page 5 of 15
(page number not for citation purposes)

BMC Systems Biology 2009, 3:52

http://www.biomedcentral.com/1752-0509/3/52

Table 3: Predicted metabolic by products

Excreted

Full

acetate
L-alanine
co2
glycine
glycerol
h+
h2o
nh4
o2
succinate

X

Full anaerobic

X

Epi anaerobic

X
X

X
X
X
X

Epimastigote

X
X

X

X

X

X
X

X

culture conditions (see table 3). While there is some
inconsistency in the literature, most experiments indicate
that byproducts of T. cruzi metabolism include succinate
[31-34], L-alanine [31,33], and CO2 [30]. Other byproducts that have been experimentally detected include acetate [31-33] and glycine [35]. These general observations
are reproduced by iSR215. In the epimastigote model,
CO2, succinate, and L-alanine are predicted byproducts of
metabolism using defined in silico conditions. We also
observed secretion of acetate and glycine using the full
model. It is possible that different sets of byproducts
could be secreted under alternative optimal solutions. To
address this possibility, we used flux variability analysis
[36]. In FVA, one seeks to find a range of flux values on
specific reactions that are compatible with maximal
growth. We found that the reactions draining succinate
and L-alanine must have non-zero flux to achieve optimal
growth in the epimastigote. In the full model, the flux on
the reaction draining succinate must be non-zero. For the
fluxes draining glycine and acetate, at least one of the two
must have a non-zero value to achieve optimal growth.
We next sought to validate iSR215 using available data on
gene or gene product essentiality in T. cruzi or related species (see table 4) [37-51]. The experimental data were collected using a variety of techniques (e.g., RNAi based
methods, pharmacological inhibition of the enzymatic
action of a certain gene product). In all, 58 test cases were
derived based on evidence from the literature, including
both the full and epimastigote models. In 46 of these
cases, our simulations correctly reproduced the experimental results, yielding 79.3% accuracy. All reactions that
were nonlethal in published literature were correctly predicted as such in the case of the full model. There were
three instances of reactions incorrectly predicted as nonessential in the full model (when compared to published
data) that were corrected by the imposition of the epimastigote constraints: 1) glycosomal triose phosphate isomerase, 2) coinhibition of fumarate reductase and succinate
dehydrogenase, and 3) coinhibition of pyruvate dehydrogenase and alpha-keto glutarate dehydrogenase. Three

reactions were wrongly predicted to be essential in the
case of the epimastigote model: 1) glycosomal fumarate
reductase, 2) pyruvate dehydrogenase, and 3) pyruvate
dehydrogenase and succinate dehydrogenase combined
inhibition. Finally, there were three cases where our predictions were incorrect in both the full and epimastigote
models: 1) malic enzyme, 2) pyruvate kinase, and 3) succinate – CoA ligase.

Discussion
Our first attempts at integrating the metabolic network
reconstruction with epimastigote stage proteomic data
provide a specific example of how constraint-based models can serve to help refine/interpret existing data. Initially, when the additional constraints arising from the
proteomic data were imposed on the genome-based
reconstruction, no solution was possible by FBA. By mapping these constraints on to iSR215, we determined that
they resulted in the loss of three critical enzyme activities:
fumarate hydratase, ribulose-5-phosphate 3-epimerase,
and glucose-6-phosphate 1-dehydrogenase. The latter two
reactions are part of the pentose phosphate pathway, leading directly to the production of key components for the
biomass demand reaction. Subsequently, we found biochemical evidence for the activity of these enzymes in epimastigotes [52]. Thus, we removed the imposed
constraints on ribulose-5-phosphate 3-epimerase and glucose-6-phosphate 1-dehydrogenase. Fumarate hydratase
was the only enzyme of the TCA cycle not detected in the
proteomics experiments. Since the TCA cycle is known to
be active in T. cruzi epimastigotes [53], we decided it was
reasonable to remove the imposed zero flux constraint
from this reaction, as well. By making these three adjustments, we obtained a positive growth rate by FBA. Thus,
the constraint-based model helped identify three cases of
probable false negative findings from the proteomics
experiments. By providing a framework for the systematic
consideration of the functional relationships between
components, the model allowed us to make more
informed judgments on the validity of the proteomic
data. An algorithmic method for integrating gene expression data into analysis of constraint-based models was
recently published [54]. Approaches such as this will
likely be invaluable for integrating proteomic and transcriptomic data with future iterations of iSR215, especially
as the scope of the model increases.
Our attempts to validate the model by comparing predicted and experimentally observed reaction lethality
should all be interpreted in light of three caveats. First, as
noted in Table 4, most of these comparisons are made,
not to T. cruzi, but to related trypanosomatid species. All
species used for our comparisons are metabolically quite
similar [30], but there are differences [32]. Second, there
are certain limitations that arise from the fact that iSR215
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Experimental Method
[ref]

Experimental Target

Model reaction(s)
constrained

Finding from literature

Full model prediction

Epimastigote model
prediction

bloodstream T. brucei***

drug-2hydroxybenzaldehyde-5phosphate [37]

fructose-1,6bisphosphate aldolase

FBAg

lethal

lethal

lethal

T. cruzi amastigotes

drug- 6phosphogluconate
analogues [38]

phosphogluconate
dehydrogenase

PGDH

lethal

lethal

lethal

T. cruzi amastigotes

drug- adenosine analogs
[39]

glyceraldehyde-3phosphate
dehydrogenase

GAPDg

lethal

lethal

lethal

T. cruzi epimastigotes

drug- bisphosphonates
[40]

hexokinase

HEXg, GLUKg

lethal

lethal

lethal

T. cruzi epimastigotes

monoclonal antibody
[41]

triosephosphate
isomerase

TPIg

lethal

nonlethal

lethal

T. cruzi epimastigotes

drug- peroxynitrite [42]

succinate dehydrogenase
and fumarate reductase*

SUCD1rm**, FRDm,
FRDgr

lethal

nonlethal

lethal

bloodstream T. brucei

RNAi [43]

phosphofructokinase

PFKg

lethal

lethal

lethal

bloodstream T. brucei

RNAi [43]

phosphoglycerate mutase

PGM

lethal

lethal

lethal

bloodstream T. brucei

RNAi [43]

enolase

ENO

lethal

lethal

lethal

procyclic T. brucei

RNAi [44]

malic enzyme

ME1x, ME1m

lethal

nonlethal

nonlethal

procyclic T. brucei

RNAi [45]

e1 alpha subunit of
pyruvate dehydrogenase,
2-oxoglutarate
dehydrogenase

PDHam1m, AKGDam1

lethal

nonlethal

lethal

bloodstream T. brucei

RNAi [43]

pyruvate kinase

PYK

lethal

nonlethal

nonlethal

procyclic T. brucei

RNAi [45]

succinyl-CoA synthetase
(succinate CoA ligase)

SUCOASm

lethal

nonlethal

nonlethal

L. donovanni
promastigotes

nontargeted gene
disruption [46]

adenosine kinase

ADK1g

nonlethal

nonlethal

nonlethal

bloodstream T. brucei

RNAi [47]

alanine aminotransferase

ALATA_L, ALATA_Lm

nonlethal

nonlethal

nonlethal

bloodstream T. brucei

RNAi [47]

cytochrome C oxidase
subunit IV

CYOO6m

nonlethal

nonlethal

nonlethal
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Table 4: Comparison of predicted and experimental reaction lethality.

RNAi [47]

glycerol-3-phosphate
dehydrogenase (FAD)

G3PDcm

nonlethal

nonlethal

nonlethal

procyclic T. brucei

RNAi [45]

e1 subunit of 2oxoglutarate
dehydrogenase

AKGDe1

nonlethal

nonlethal

nonlethal

procyclic T. brucei

RNAi [44]

F1 complex of ATP
synthase

ATPSm

nonlethal

nonlethal

nonlethal

procyclic T. brucei

RNAi [48]

glycosomal NADHdependent fumarate
reductase

FRDgr

nonlethal

nonlethal

lethal

procyclic T. brucei

RNAi [44]

mitochondrial fumarate
reductase

FRDm

nonlethal

nonlethal

nonlethal

procyclic T. brucei

RNAi [45]

e1 alpha subunit of
pyruvate dehydrogenase

PDHam1m

nonlethal

nonlethal

lethal

procyclic T. brucei

RNAi [45]

e1 alpha subunit of
pyruvate dehydrogenase,
succinate dehydrogenase

PDHam1m, SUCD1rm

nonlethal

nonlethal

lethal

procyclic T. brucei

RNAi [44]

phosphoenolpyruvate
carboxykinase

PPCKg

nonlethal

nonlethal

nonlethal

procyclic T. brucei

RNAi [44]

proline oxidase

PRO1xm

nonlethal

nonlethal

nonlethal

procyclic T. brucei

RNAi [45]

succinate dehydrogenase

SUCD1rm

nonlethal

nonlethal

nonlethal

bloodstream T. brucei

targeted gene disruption
[49]

aconitase

ACONTm

nonlethal

nonlethal

nonlethal

procyclic T. brucei

targeted gene disruption
[50]

acetyl:succinate CoAtransferase

ASCTmr

nonlethal

nonlethal

nonlethal

procyclic T. brucei

targeted gene disruption
[51]

pyruvate phosphate
dikinase

PPDKg

nonlethal

nonlethal

nonlethal

*Hypothesized to be the main targets of peroxynitrite in T. cruzi
**Succinate dehydrogenase is represented in the model by two reactions, SUCD1rm, and SUCD3-u6m; inhibition of succinate dehydrogenase simulated by inhibiting the first of these two
***One variation of compound was lethal for T. cruzi, as well
See references [37-51] for details.
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is not a genome-scale model; these are discussed in more
detail below. Third, the experimental data used were collected using complex, undefined culture media that we
could not reproduce in silico. The overall accuracy of our
predictions (79.3%) is comparable to that reported for
other organisms, e.g., 83% for Saccharomyces cerevesiae [4],
70% for Leishmania major [55], 91% for Escherischia coli
[56].
We found three instances of reactions incorrectly predicted as nonessential in the full model that were corrected by the imposition of the epimastigote constraints
when compared with published literature (see Table 4): 1)
glycosomal triose phosphate isomerase, 2) coinhibition
of fumarate reductase and succinate dehydrogenase, and
3) coinhibition of pyruvate dehydrogenase and alphaketo glutarate dehydrogenase. This observation suggests
that the additional epimastigote constraints correctly
eliminate certain steady state metabolisms that would
otherwise be available to the parasite according to the full
model. It is noteworthy that cases 1) and 2) are the only
ones in which available experimental data were collected
specifically in T. cruzi epimastigotes, as opposed to other
morphological stages or related trypanosomatid species.
Three activities were wrongly predicted to be essential in
the case of the epimastigote model when compared to
published data (see Table 4): 1) glycosomal fumarate
reductase, 2) pyruvate dehydrogenase, and 3) pyruvate
dehydrogenase and succinate dehydrogenase combined
inhibition. Of course, if pyruvate dehydrogenase is predicted to be essential, it is to be expected that inhibition
of additional reactions (e.g., succinate dehydrogenase)
along with pyruvate dehydrogenase would also be predicted as essential. We left these as independent predictions since we did not know a priori whether neither, one,
or both would be predicted as essential. Thus 3) is incorrect because 2) is incorrect. The reason that 2) is incorrect
is that without pyruvate dehyrogenase, there is no way to
produce acetyl-CoA in the core metabolic model (and no
other route for consuming CoA produced in the mitochondrion). Adding an additional source of acetyl-CoA
and sink for mitochondrial CoA results in a positivegrowth solution by FBA. Threonine dehydrogenase, which
might otherwise produce acetyl-CoA is inactivated in the
epimastigote model. Glycosomal fumarate reductase is
also incorrectly predicted to be essential in the epimastigote case. The reason for this incorrect prediction is that
without glycosomal fumarate reductase, there is no existing route to stoichiometrically convert NADH back to
NAD inside the glycosome. Adding such a process back to
the model results in a positive-growth solution by FBA.
Glycerol-3-phosphate dehydrogenase and glycerol kinase
could fill this role, but they are inactivated in the epimastigote model. Thus, these incorrect predictions may be

http://www.biomedcentral.com/1752-0509/3/52

either due to the incomplete nature of the model (e.g.,
another route for acetyl-CoA production that is not represented in iSR215) or perhaps because of possible changes
in protein expression that are not explicitly represented in
the model (e.g., glycerol-3-phosphate dehydrogenase and
glycerol kinase expression may be conditionally induced
in epimastigotes).
Finally, there were three examples in which our predictions were incorrect in both the full and epimastigote
models: 1) malic enzyme, 2) pyruvate kinase, and 3) succinate – CoA ligase. Here again, these discrepancies are
likely due to the fact that the core model remains incomplete. Specifically, we have not attempted to fully account
for proton gradients in T. cruzi. Therefore, synthesis via
oxidative phosphorylation is coupled not only to the
pumping of hydrogen ions by the respiratory chain but
also to the production of hydrogen ions by cytoplasmic
processes. Thus, the contribution of oxidative phosphorylation to total ATP synthesis suggested by iSR215 is likely
to be an overestimate of the true contribution. In fact, the
majority of ATP synthesis in these parasites is thought to
be via substrate level phosphorylation [30]. This explanation seems to account for the incorrect prediction in the
case of succinate – CoA ligase; when mitochondrial ATP
synthase is constrained to zero flux, the succinate – CoA
ligase reaction is essential. The reasons for the incorrect
prediction for malic enzyme and pyruvate kinase are less
clear. Again, it may be a reflection of the incomplete
nature of the core model, i.e., there are processes not
included in iSR215, which are dependent on the production or consumption of metabolites that these reactions
entail. Overall, the accuracy of the model at this stage is
encouraging.

Conclusion
We have presented the first constraint-based metabolic
model and analysis of T. cruzi, the protozoan parasite
responsible for Chagas disease. This model accounts for
central metabolic processes such as ATP generation and
production of key intermediate metabolites. Moreover,
the model includes three major intracellular compartments: the glycosome (a characteristic feature of T. cruzi
and other trypanosomes), the mitochondrion, and the
cytosol. Thus, many key features of trypanosomatid
metabolism are represented. Most reactions in the model
are supported by both direct biochemical evidence from
the primary literature and by the genome annotation of T.
cruzi. Many aspects of the cellular physiology and data
concerning gene/reaction essentiality are accurately captured by iSR215. Future work on iSR215 will initially be
focused on expanding the scope of the model to include
all known T. cruzi metabolic reactions using procedures
similar to those described here. Previous experience suggests that as the model is expanded and refined through
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successive iterations, the accuracy of the essentiality predictions will improve [3,57-59]. We have used a wide variety of evidence in constructing this model, namely
genomic, proteomic, and information drawn from primary literature. This gives us a fairly high level of confidence in what is currently included in the model.
Our incorporation of several replicate high-throughput
proteomic data sets illustrates the integrative capabilities
of constraint-based models. This data was used to further
constrain the space of possible solutions and enabled us
to examine stage-specific aspects of metabolism. In the
available instances where experimental confirmation was
available for T. cruzi epimastigotes specifically, applying
the proteomic constraints produced the correct prediction; without these additional constraints, the model prediction was incorrect. Constraints reflecting data on gene
expression have previously been shown to improve the
accuracy of constraint-based model predictions [60,61].
Our experience also indicates that constraint-based models may aid in the interpretation of such high-throughput
datasets, potentially helping to identify false negative
results. Proteomics data are imperfect, and false negative
results tend to be more of a concern than false positives.
We attempted to minimize false negatives experimentally
by using sub-cellular proteomics techniques (see Methods). This approach proved quite useful, as the number of
identified proteins increased by more than 50% over traditional shotgun-based methods (data not shown). Even
so, there were three examples of probable false-negative
findings that were revealed by considering the proteomics
data in light of iSR215 (see discussion of fumarate
hydratase, ribulose-5-phosphate 3-epimerase, and glucose-6-phosphate 1-dehydrogenase, above). Thus, constraint-based models can provide a systematic framework
for the interpretation and evaluation of findings from proteomics experiments.
Our comprehensive gene and reaction deletion testing
illustrates the way in which constraint based models can
become tools for drug discovery. Each of these predictions
represents a testable hypothesis. Assuming that at least
some of the reactions predicted to be essential are experimentally verified, these suggest points of vulnerability in
the parasite's metabolism, which could potentially be
exploited to develop new, urgently needed chemotherapeutics. Additionally, model-based predictions of the
effect of combined environmental manipulations and
specific reaction inhibitors can be generated using this
model.

Methods
Metabolic Reconstruction
The theoretical basis and procedures underlying construction and analysis of constraint-based models have been

http://www.biomedcentral.com/1752-0509/3/52

extensively reviewed [6,8]. The process of network reconstruction involves data collection, metabolic reaction list
generation, and determination of gene-protein-reaction
relations. The sources of information used for our network reconstruction were: publicly available annotations
of the T. cruzi genome (UniProt [62], KEGG [63], GeneDB
[64]), our in-house annotation of the T. cruzi genome (JM
Alves, unpublished), information from biochemistry textbooks and standard databases (e.g., KEGG), and primary
biochemical literature on T. cruzi or closely related species
(e.g., Trypanosoma brucei, Leishmania major). To identify
relevant primary biochemical literature, we searched
PUBMED for review articles on Trypanosomatid metabolism, with special focus on the pathways of central metabolism (e.g., search term "Trypanosoma cruzi glycolysis").
For individual reactions under consideration, we searched
using a common variant of the reaction name, plus T.
cruzi or the name of a related species (e.g., search term
"Trypanosoma cruzi hexokinase"). We examined hundreds
of articles in detail and screened the abstracts of many
more. While we cannot claim to have exhausted the literature on T. cruzi metabolism, we searched to the point of
reaching a high degree of confidence for most reactions in
the model (i.e., that these reactions do, in fact, occur in T.
cruzi). In some cases, references sought in connection with
one reaction were found to report activity measurements
corresponding to other model reactions. The recently published genome-scale constraint based model of L. major
was also used as a guide in model construction and analysis [55]. These information sources were used to compile
the metabolic reaction list, including reaction stoichiometry, reversibility, sub-cellular localization, and gene
locus/loci for each reaction comprising core metabolism.
The relations between genes, gene products and metabolic
reactions were encapsulated in Boolean gene-productreaction (GPR) statements (e.g., gene A codes for protein
X or protein Y, protein X and protein P together catalyze
reaction R, etc.).
We defined core metabolism as those metabolic reactions
directly or closely related to energy generation (ATP) or
involved in production of critical metabolites (see Biomass Equation, below). Transports between intracellular
compartments were often represented as simple, bidirectional diffusion reactions, or occasionally as co-transports
with hydrogen ions, as there currently are no data to suggest more specific mechanisms. This approach has proven
useful as a first approximation for representing eukaryotic
intracellular transport processes [4].
The glycosome is thought to be relatively impermeable to
metabolites, especially to adenine nucleotides and
NAD(H) [30]. Therefore in our reconstruction, we
required that the glycosome be both energy balanced
(ATP production balances ATP consumption) and reduc-
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tion-oxidation balanced (NADH production balances
NADH consumption). We imposed these constraints simply by excluding transports between the cytosol and glycosome for these and related (e.g., ADP, NAD+)
metabolites.

Mathematically, S is a transformation of the reaction flux
vector, v, to a vector of time derivatives for each metabolite concentration:

Once the network was reconstructed, the list of metabolic
reactions was transformed into a stoichiometric matrix
(S), i.e., the mathematical representation of the reconstructed network. The dimensions of the S matrix are m ×
n, where m is the number of metabolites and n is the
number of reactions. Each element Sij represents the stoichiometric coefficient of metabolite i in reaction j. If the
metabolite in a particular reaction is a reactant, the coefficient is negative (the metabolite is consumed by the reaction); if it is a product, the coefficient is positive (the
metabolite is produced by the reaction). The S matrix was
then used as the basis of further analysis, i.e., Flux Balance
Analysis (FBA, see below). Model construction and analysis were carried out using SimPheny (Genomatica, Inc.).

Since the time constants for metabolic transients are fast
(< tens of seconds), but the time constants for cell growth
are long (hours to days), the metabolites can be considered as existing in a quasi-steady state [6]. This leads to the
second equation of the LP optimization problem above.
Because of the emphasis on steady states, assumptions
regarding reaction kinetics are not needed. Note also that
in silico growth conditions can be defined via ai and bi. For
example, if an analysis is to be conducted with glucose,
but not glycerol, as an available metabolite, the flux for a
process corresponding to glucose input would be assigned
some nonzero positive maximal value, while the flux for
a process corresponding to glycerol input would be constrained to be zero (ai = bi = 0). In all of our FBA simulations, we allowed the following extracellular metabolites
to enter the system: glucose, glutamate, proline, aspartate,
threonine, phosphate, CO2, water, and NH4; oxygen was
allowed to enter in aerobic, but not anaerobic, simulations. The following extracellular metabolites were
allowed to leave the system: succinate, alanine, glycine,
acetate, glycerol, oxygen, water, CO2, NH4, and hydrogen.

Naming Convention
We follow the previously established convention of naming constraint-based models [3]. Model names begin with
'i' to denote in silico, followed by the first author's first and
last initials ('SR'), followed by the number of genes that
are part of the model ('215').
Flux Balance Analysis
Once constructed, the constraint-based model was analyzed using FBA. In essence, FBA uses linear programming
(LP) based optimization to identify a particular flux distribution (a single point in the multidimensional space of
possible metabolic behaviors) that optimizes a given metabolic objective (see Biomass Equation, below). The LP
optimization problem is formulated as:

Maximize Z,
Subject to S·v = 0,
a i ≤ v i ≤ b i for all reactions i.
Z is the objective function; for this study, Z was defined as
the biomass equation (see below). The second two statements are the flux constraints. S is the stoichiometric
matrix defined above. Each reaction flux is subject to
lower and upper bounds, as indicated (in cases where
these are not known, ai and bi are set to some arbitrary
numbers that exceed any feasible internal flux). The solution to this problem is an optimal flux distribution, v, a
vector that contains flux values for each reaction in the
network. The solution is optimal in the sense that it maximizes the flux through the objective Z.

S•v = dx / dt.

We also incorporated information from the literature on
maximal rate of uptake of glucose and amino acids where
possible. For example, Vmax for glucose uptake in T. cruzi
has been reported as ~46 nmol/min per mg of protein
[65]. Given that ~47% of T. cruzi dry weight is protein
[66], this corresponds to ~1.31 mmol/hr per gm dry
weight. Since transport of both the alpha and beta anomers of glucose is explicitly represented in the model, we
simply set the maximum flux (bi) on each reaction to
~0.65 mmol/hr per gm dry weight. In a similar fashion the
maximum flux on glutamate uptake was set to ~0.027
[67], on proton symport-based proline transport to
~0.0036 [68], on ATP-dependant proline transport to
~0.020 [68], for aspartate uptake to ~0.0020 [69], and on
threonine uptake to ~0.01 (approximation based on
experimental values for the other transporters).
Biomass Equation
In FBA, optimization is used to find a particular flux distribution that maximizes a given metabolic objective. Typical metabolic objectives chosen for optimization include
maximization of ATP production, byproduct secretion, or
biomass production. In our work, we chose to optimize
for biomass production [70]. Biomass production is represented in our model by an additional metabolic reaction. Its reactants include such critical metabolites as ATP,
acetyl-CoA, and NADPH; its products include ADP, inor-
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ganic phosphate, and other metabolites that represent
byproducts of anabolic metabolism. This particular equation and its stoichiometric coefficients were derived from
the biomass requirements for Bacillus subtilis [71]. These
requirements were established for B. subtilis using detailed
modeling and isotopic tracer data. In constructing our
equation, we made several minor changes to the biomass
requirements previously reported, simply to account for
the fact that iSR215 does not include certain metabolites
and to enable cycling of cofactors. Although the exact
requirements of B. subtilis for critical metabolites are no
doubt different from those of T. cruzi, previous work has
demonstrated that FBA results are relatively insensitive to
changes in biomass component stoichiometric coefficients [72].
Reaction Deletions
To simulate the effect of deleting reactions, we constrained each of the reactions in turn to have zero flux (ai
= bi = 0) and reran FBA in each case. If no solution was
found (biomass reaction flux = 0), the reaction was
deemed essential; if a solution was found, the reaction
was deemed nonessential.
Validation
To validate our model, we attempted to replicate findings
from the biochemical literature. We used findings from
experiments involving targeted disruption of genes or
gene products (gene knockouts, RNAi, or drugs to block
specific enzymes) in T. cruzi or related organisms. Similar
manipulations were made using iSR215, and the in silico
and experimental results were compared.
Epimastigote Specific Metabolism
The life cycle of T. cruzi is complex [15]. In the mammalian host, T. cruzi replicates intracellularly, as a nearly
spherical amastigote, in many cell types. Rupture of the
cell releases non-dividing trypomastigotes, which circulate and infect cells in remote organs and tissues. When
ingested by blood sucking insect vectors, trypomastigotes
transform and replicate as epimastigotes in the insect
digestive tract. Epimastigotes are rapidly lysed by complement and are not infective for mammalian hosts. Conditions in the colon and rectum of the reduviid bug induce
metacyclogenesis, or differentiation of non-infectious epimastigotes into infectious metacyclic trypomastigotes.
The cycle is completed when the bug deposits contaminated excreta near the bite wound and the metacyclic trypomastigotes are mechanically introduced into the host.
The metacyclic trypomastigotes are complement resistant
and circulate in the host briefly prior to infecting a host
cell.

http://www.biomedcentral.com/1752-0509/3/52

tigote stage. We performed both 2D gel analysis and 2D
nano LC MS/MS to produce proteomic data for T. cruzi
epimastigotes. We used these data to further constrain
iSR215 to be epimastigote-specific. Epimastigotes were
grown exponentially in LIT medium, supplemented with
10% fetal calf serum, and different subcellular fractions
were collected using subcellular proteome kit (ProteoExtract, Subcellular Proteome Extraction Kit, Calbiochem).
Each fraction was submitted to 2D nano LC MS/MS, as
previously described [73]. Proteins were identified by
searching the MS/MS spectra against our T. cruzi database
using Bioworks v3.2. Peptide and protein hits were scored
and ranked using the new probability-based scoring algorithm incorporated in Bioworks v3.2. Peptides identified
as possessing fully tryptic termini with acceptable crosscorrelation scores (greater than 1.9 for singly charged peptides, 2.3 for doubly charged peptides, and 3.75 for triply
charged peptides), with delta Cn greater than 0.25, and
with a probability score of less than 0.0001 were initially
accepted. For increased stringency we used reverse database search to adjust the above scores to obtain less than
1% false discovery rate. Proteins that passed this final criterion were accepted for use in the model.
The model resulting from the procedures described in
"Metabolic Reconstruction" above was designated as the
"full model," since all reactions included could operate at
non-zero flux values. We used the proteomics results to
apply further constraints to the full model, resulting in a
stage-specific "epimastigote model." Specifically, if there
was no evidence at the protein level supporting the existence of a specific metabolic reaction in epimastigotes,
then that metabolic reaction was constrained to a flux
value of zero (ai = bi = 0, see above). For example, the protein responsible for glucokinase activity (reaction ID
"GLUKg") was detected in the epimastigote by our proteomics experiments; therefore, no special constraint was
applied to this reaction. On the other hand, the proteins
responsible for aldose 1-epimerase activity (A1Eg) were
not detected by the proteomics experiments; therefore,
this reaction was constrained to have zero flux, since the
data suggested no enzymes to catalyze the reaction were
expressed. For reactions requiring multiple proteins, we
allowed the reaction to occur if there was evidence for the
expression of any of the corresponding proteins in the
proteomics data.
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